BACKGROUND: Thrombocytopenia after transcatheter aortic valve replacement (TAVR) is associated with adverse clinical outcomes. Whether preprocedural P2Y12 inhibition prevents postprocedural thrombocytopenia is uncertain. METHODS: This retrospective analysis identified consecutive patients (n = 266) undergoing TAVR between November 2016 and July 2017. Preprocedure clopidogrel load ≥300 mg or maintenance P2Y12 inhibitor therapy defined preprocedural P2Y12 inhibition. Patients who did not consent for the registry (n = 8), with baseline severe thrombocytopenia (<90 × 103 platelets/μL; n = 14), or without baseline platelet count (n = 4) were excluded. The primary outcome was proportion of patients who developed >20% decrease in platelet count from baseline to day 1 post-TAVR. RESULTS: Patients with (n = 134) versus without (n = 106) preprocedural P2Y12 inhibition had no differences in platelet count at baseline. Patients with preprocedural P2Y12 inhibition had a significantly lower proportion of the primary outcome (34.3% vs. 57.5%, p = .001) and a lower absolute decrease in platelet count (32.8 × 103 vs. 45.8 × 103 platelet/μL, p = .01). Of patients without baseline thrombocytopenia (n = 198), a numerically lower rate of patients with versus without preprocedural P2Y12 inhibition developed thrombocytopenia on day 1 post-TAVR (25.5% vs. 36.4%, p = .1). CONCLUSION: Patients who received preprocedural P2Y12 inhibition prior to TAVR were less likely to demonstrate a decrease in platelet count after TAVR. Prospective studies to further understand the clinical implication of these findings are warranted.
BACKGROUND:Thrombocytopenia after transcatheter aortic valve replacement (TAVR) is associated with adverse clinical outcomes. Whether preprocedural P2Y12 inhibition prevents postprocedural thrombocytopenia is uncertain. METHODS: This retrospective analysis identified consecutive patients (n = 266) undergoing TAVR between November 2016 and July 2017. Preprocedure clopidogrel load ≥300 mg or maintenance P2Y12 inhibitor therapy defined preprocedural P2Y12 inhibition. Patients who did not consent for the registry (n = 8), with baseline severe thrombocytopenia (<90 × 103 platelets/μL; n = 14), or without baseline platelet count (n = 4) were excluded. The primary outcome was proportion of patients who developed >20% decrease in platelet count from baseline to day 1 post-TAVR. RESULTS:Patients with (n = 134) versus without (n = 106) preprocedural P2Y12 inhibition had no differences in platelet count at baseline. Patients with preprocedural P2Y12 inhibition had a significantly lower proportion of the primary outcome (34.3% vs. 57.5%, p = .001) and a lower absolute decrease in platelet count (32.8 × 103 vs. 45.8 × 103 platelet/μL, p = .01). Of patients without baseline thrombocytopenia (n = 198), a numerically lower rate of patients with versus without preprocedural P2Y12 inhibition developed thrombocytopenia on day 1 post-TAVR (25.5% vs. 36.4%, p = .1). CONCLUSION:Patients who received preprocedural P2Y12 inhibition prior to TAVR were less likely to demonstrate a decrease in platelet count after TAVR. Prospective studies to further understand the clinical implication of these findings are warranted.
Authors: David R Holmes; Michael J Mack; Sanjay Kaul; Arvind Agnihotri; Karen P Alexander; Steven R Bailey; John H Calhoon; Blase A Carabello; Milind Y Desai; Fred H Edwards; Gary S Francis; Timothy J Gardner; A Pieter Kappetein; Jane A Linderbaum; Chirojit Mukherjee; Debabrata Mukherjee; Catherine M Otto; Carlos E Ruiz; Ralph L Sacco; Donnette Smith; James D Thomas Journal: J Am Coll Cardiol Date: 2012-01-31 Impact factor: 24.094
Authors: J L Moake; C K Rudy; J H Troll; M J Weinstein; N M Colannino; J Azocar; R H Seder; S L Hong; D Deykin Journal: N Engl J Med Date: 1982-12-02 Impact factor: 91.245
Authors: Tarun Chakravarty; Lars Søndergaard; John Friedman; Ole De Backer; Daniel Berman; Klaus F Kofoed; Hasan Jilaihawi; Takahiro Shiota; Yigal Abramowitz; Troels H Jørgensen; Tanya Rami; Sharjeel Israr; Gregory Fontana; Martina de Knegt; Andreas Fuchs; Patrick Lyden; Alfredo Trento; Deepak L Bhatt; Martin B Leon; Raj R Makkar Journal: Lancet Date: 2017-03-19 Impact factor: 79.321
Authors: Josep Rodés-Cabau; Jean-Bernard Masson; Robert C Welsh; Bruno Garcia Del Blanco; Marc Pelletier; John G Webb; Faisal Al-Qoofi; Philippe Généreux; Gabriel Maluenda; Martin Thoenes; Jean-Michel Paradis; Chekrallah Chamandi; Vicenç Serra; Eric Dumont; Mélanie Côté Journal: JACC Cardiovasc Interv Date: 2017-05-17 Impact factor: 11.195
Authors: Samir Kapadia; Shikhar Agarwal; D Craig Miller; John G Webb; Michael Mack; Stephen Ellis; Howard C Herrmann; Augusto D Pichard; E Murat Tuzcu; Lars G Svensson; Craig R Smith; Jeevanantham Rajeswaran; John Ehrlinger; Susheel Kodali; Raj Makkar; Vinod H Thourani; Eugene H Blackstone; Martin B Leon Journal: Circ Cardiovasc Interv Date: 2016-09 Impact factor: 6.546
Authors: Danny Dvir; Philippe Généreux; Israel M Barbash; Susheel Kodali; Itsik Ben-Dor; Mathew Williams; Rebecca Torguson; Ajay J Kirtane; Sa'ar Minha; Salem Badr; Lakshmana K Pendyala; Joshua P Loh; Petros G Okubagzi; Jessica N Fields; Ke Xu; Fang Chen; Rebecca T Hahn; Lowell F Satler; Craig Smith; Augusto D Pichard; Martin B Leon; Ron Waksman Journal: Eur Heart J Date: 2014-03-04 Impact factor: 29.983
Authors: Michael J Mack; J Matthew Brennan; Ralph Brindis; John Carroll; Fred Edwards; Fred Grover; David Shahian; E Murat Tuzcu; Eric D Peterson; John S Rumsfeld; Kathleen Hewitt; Cynthia Shewan; Joan Michaels; Barb Christensen; Alexander Christian; Sean O'Brien; David Holmes Journal: JAMA Date: 2013-11-20 Impact factor: 56.272
Authors: V J Nijenhuis; P R Stella; J Baan; B R G Brueren; P P de Jaegere; P den Heijer; S H Hofma; P Kievit; T Slagboom; A F M van den Heuvel; F van der Kley; L van Garsse; K G van Houwelingen; A W J Van't Hof; J M Ten Berg Journal: Neth Heart J Date: 2014-02 Impact factor: 2.380